Literature DB >> 12967946

Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse.

Margaret A Smith-White1, Tiina P Iismaa, Erica K Potter.   

Abstract

(1) This study investigated the effects of galanin (GAL) on inhibition of cholinergic (vagal) activity in the mouse heart using control galanin knockout (GAL-KO) and GAL-1R receptor knockout (GAL-1R-KO) mice. (2) In pentobarbitone anaesthetised mice, supramaximal stimulation every 30 s of the vagus nerve innervating the heart, increased pulse interval (PI) by approximately 50 ms or decreased heart rate by approximately 100 beats min-1. This response was attenuated by intravenous administration of GAL (dose ranged from 0.8 to 13 nmol kg-1) in a dose-dependent manner. (3) In GAL-KO mice, the magnitude of inhibition of the increase in PI (DeltaPI) following a bolus dose of GAL was not different from the DeltaPI in control mice, and neuropeptide Y (NPY), previously shown to attenuate vagal inhibitory activity in mice, evoked a comparative inhibition of DeltaPI in GAL-KO mice. (4) In GAL-1R-KO mice, an intravenous, bolus injection of GAL had no inhibitory effect on vagal activity. (5) In control mice, stimulation of the sympathetic nerve at 25 V, 10 Hz for 2 min in the presence of propranolol evoked a long-lasting attenuation of DeltaPI. The inhibitory effect on DeltaPI was reduced in the presence of the NPY Y2 antagonist, BIIE0246. (6) In GAL-1R-KO mice, stimulation of the sympathetic nerve in the presence of propranolol evoked an attenuation of DeltaPI not significantly different from the response in control mice in the presence of BIIE0246. Following administration of BIIE0246 in GAL-1R-KO mice, the inhibition of DeltaPI that followed stimulation of the sympathetic nerve was abolished. (7) These findings support the view that the nerve terminals of parasympathetic neurons in the mouse heart possess both GAL-1R and NPY Y2 receptors which, when activated, reduce acetylcholine release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967946      PMCID: PMC1574002          DOI: 10.1038/sj.bjp.0705404

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.

Authors:  H Doods; W Gaida; H A Wieland; H Dollinger; G Schnorrenberg; F Esser; W Engel; W Eberlein; K Rudolf
Journal:  Eur J Pharmacol       Date:  1999-11-19       Impact factor: 4.432

Review 2.  Galanin and galanin receptors.

Authors:  T P Iismaa; J Shine
Journal:  Results Probl Cell Differ       Date:  1999

3.  Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity.

Authors:  Arie Steven Jacoby; Yvonne Janet Hort; George Constantinescu; John Shine; Tiina Pauline Iismaa
Journal:  Brain Res Mol Brain Res       Date:  2002-11-15

4.  Distribution of galanin-like immunoreactivity in the gastro-intestinal tract of several mammalian species.

Authors:  T Melander; T Hökfelt; A Rökaeus; J Fahrenkrug; K Tatemoto; V Mutt
Journal:  Cell Tissue Res       Date:  1985       Impact factor: 5.249

5.  Cardiac sympathetic nerves in rats: anatomical and functional features.

Authors:  K Yasunaga; S Nosaka
Journal:  Jpn J Physiol       Date:  1979

6.  Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y?

Authors:  E K Potter
Journal:  Neurosci Lett       Date:  1985-03-15       Impact factor: 3.046

7.  Galanin - a novel biologically active peptide from porcine intestine.

Authors:  K Tatemoto; A Rökaeus; H Jörnvall; T J McDonald; V Mutt
Journal:  FEBS Lett       Date:  1983-11-28       Impact factor: 4.124

8.  Vagal stimulation and cardiac slowing.

Authors:  P Parker; B G Celler; E K Potter; D I McCloskey
Journal:  J Auton Nerv Syst       Date:  1984-09

9.  Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission.

Authors:  Margaret A Smith-White; Herbert Herzog; Erica K Potter
Journal:  Regul Pept       Date:  2002-02-15

10.  Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions.

Authors:  M A Smith-White; T A Hardy; J A Brock; E K Potter
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

View more
  13 in total

1.  Cardiac ischemia-reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms.

Authors:  Eric N Alston; Diana C Parrish; Wohaib Hasan; Kevin Tharp; Laura Pahlmeyer; Beth A Habecker
Journal:  Neuropeptides       Date:  2010-10-28       Impact factor: 3.286

2.  Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion.

Authors:  Cláudia Cavadas; Daniel Céfai; Joana Rosmaninho-Salgado; Maria Augusta Vieira-Coelho; Eduardo Moura; Nathalie Busso; Thierry Pedrazzini; Daniela Grand; Samuel Rotman; Bernard Waeber; Jean-François Aubert; Eric Grouzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-23       Impact factor: 11.205

3.  Remodeling of stellate ganglion neurons after spatially targeted myocardial infarction: Neuropeptide and morphologic changes.

Authors:  Olujimi A Ajijola; Daigo Yagishita; Naveen K Reddy; Kentaro Yamakawa; Marmar Vaseghi; Anthony M Downs; Donald B Hoover; Jeffrey L Ardell; Kalyanam Shivkumar
Journal:  Heart Rhythm       Date:  2015-01-30       Impact factor: 6.343

4.  Cardiac sympathetic activation circumvents high-dose beta blocker therapy in part through release of neuropeptide Y.

Authors:  Jonathan D Hoang; Siamak Salavatian; Naoko Yamaguchi; Mohammed Amer Swid; Hamon David; Marmar Vaseghi
Journal:  JCI Insight       Date:  2020-06-04

Review 5.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.

Authors:  Julia Shanks; Neil Herring
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-04       Impact factor: 3.619

6.  Post-infarct cardiac sympathetic hyperactivity regulates galanin expression.

Authors:  T Jarred Ewert; Kurt R Gritman; Michael Bader; Beth A Habecker
Journal:  Neurosci Lett       Date:  2008-03-18       Impact factor: 3.046

7.  Exercise benefits cardiovascular health in hyperlipidemia rats correlating with changes of the cardiac vagus nerve.

Authors:  You-Hua Wang; Hao Hu; Sheng-Peng Wang; Zhen-Jun Tian; Quan-Jiang Zhang; Qiu-Xia Li; You-You Li; Xiao-Jiang Yu; Lei Sun; Dong-Ling Li; Bing Jia; Bing-Hang Liu; Wei-Jin Zang
Journal:  Eur J Appl Physiol       Date:  2009-10-15       Impact factor: 3.078

8.  Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors.

Authors:  Eckhard Schwertfeger; Thomas Klein; Oliver Vonend; Vitus Oberhauser; Johannes Stegbauer; Lars Christian Rump
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-22       Impact factor: 3.000

9.  Neuropeptide Y and gamma-melanocyte stimulating hormone (gamma-MSH) share a common pressor mechanism of action.

Authors:  Kenneth A Gruber; Wei Fan; Helena Akerberg; Dan Larhammar; Melissa J S Chee; William F Colmers; Roger D Cone
Journal:  Endocrine       Date:  2009-04-11       Impact factor: 3.633

10.  The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability.

Authors:  Neil Herring; James Cranley; Michael N Lokale; Dan Li; Julia Shanks; Eric N Alston; Beatrice M Girard; Emma Carter; Rodney L Parsons; Beth A Habecker; David J Paterson
Journal:  J Mol Cell Cardiol       Date:  2011-12-07       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.